Zum Seiteninhalt springen
Deutschland

Fakten & Zahlen 

Seit über 20 Jahren widmet sich AOP Health der pharmazeutischen und klinischen Entwicklung sowie der Kommerzialisierung von Arzneimitteln. 

Unsere Motivation bei der AOP Health ist es, Patient*innen, die an seltenen Erkrankungen leiden, zu helfen. Dies erreichen wir in der Zusammenarbeit mit den Stakeholdern des deutschen Gesundheitssystems. Kooperationen in der Pharma- und Gesundheitsbranche sind entscheidend um die Lösungen für PatientInnen entwickeln zu können und diese verfügbar zu machen -  insbesondere bei der Behandlungen von seltenen und komplexen Erkrankungen.

AOP Health ist in vielen Ländern vertreten, allerdings nimmt Deutschland eine Sonderstellung ein, da das Land eines der ersten Expansionen des Unternehmens gewesen. AOP Health Deutschland begann seine Entwicklung im Jahre 2011 und wurde 2018 in eine juristische Person umgewandelt. 

AOP Health Deutschland ist ein Team von 18 Mitarbeiter*innen in den Bereichen Marketing & Vertrieb, Medical, Market Access, Accounting, Controlling, HR und Office Management.

4mio
Menschen
MENSCHEN MIT SELTENEN ERKRANKUNGEN IN deutschland
In Europa liegt eine seltene Erkrankung vor wenn weniger als 5 Personen pro 10,000 Einwohner betroffen sind. In Deutschland leben rund 4 mio Menschen mit einer seltenen Erkrankung
HämatoOnkologie
Derzeit ist AOP Health Deutschland spezialisiert auf therapeutische Lösungen für HämatoOnkologie.
HON
bereich
3
PRODUkte
3 Innovative Produkte
In Deutschland stellt AOP Health derzeit drei Therapien und Medikamente zu Verfügung.

Vision & Mission

Milestones

History of more than 20 years means many significant milestones — in research,  social, business spheres and regulatory affairs — that were and are important for AOP Health.

2022

2022 – New brand name: AOP Health

The brand name was changed to AOP Health to reflect the expansion of business activities beyond rare diseases covering all of the Group’s business segments including critical care.

2020

AOP Orphan Group

AOP Orphan took over the Viennese pharmaceutical company Amomed and the Luxembourgish health-tech company SciPharm.

2019

BESREMi® Approval

On Feb 15th EMA approves AOP Orphan’s BESREMi® as firt-line monotherapy in adults for the treatment of Polycytheamia vera (PV) without symptomatic splenomegaly.

2018

Treprostinil and PAH

The paper “Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial" was published by R. Sadushi-Kolici R; Jansa P; Kopec G; Torbicki A; Skoro-Sajer N; Campean IA; Halank M; Simkova I; Karlocai K; Steringer-Mascherbauer R; Samarzija M; Salobir B; Klepetko W; Lindner J; Lang IM (Source: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(18)30367-9/fulltext). The authors conclude that sc. Treprostinil significantly improves the cardiovascular situation and performances figure of patients with CTREPH.

2017

Landiolol approval

Landiolol, a new ultra-high selective short acting beta 1 adrenoceptor blocker, developed by AOP in 2 forms (20 mg/2ml concentrate, 300 mg powder) is registered in several European countires for the treatment of non-compensatory sinus tachycardia and tachycardic supraventricular arrhythmias. The drug uses a new AOP Orphan-developed dosing algorithm to facilitate the administration and proves to be superior to Esmolol in its ability to reduce heart rate more than blood pressure.

2016

Pitolisant approval

Pitolisant, also known as tiprolisant, is a potent and selective inverse agonist of the histamine H3 receptor (Ki = 0.16 nM), and was approved for the treatment of narcolepsy in 2016. Pitolisant was developed by Jean-Charles Schwartz, Walter Schunack, and colleagues, after the former discovered the H3 receptor. It was the first H3 receptor inverse agonist to be tested in humans or introduced for clinical use.

2015

Beta-blocker for severe sepsis

The paper “Beta-blocker use in severe sepsis and septic shock: a systematic review.” by Sanfilippo F1, Santonocito C2, Morelli A3, Foex P4 describes the ability of beta blockade to modulate sepsis-induced alterations at the cardiovascular, metabolic, immunologic and coagulation levels.

2013

Start of the PROUD PV Study

The PROUD-PV study is a phase III study to compare the efficacy and safety of the novel ropeginterferon α-2b versus hydroxyurea in both HU-naive and currently treated patients, diagnosed with Polycythemia vera.

2012

Nabilone Approval in Austria

Nabilone is a synthetically produced substance belonging to a group of compounds known as cannabionoids, used for the treatment of CINV.

2010

Tetrabenazine Approval in Central Europe

Tetrabenazine approval for the treatment of Huntington's chorea in 23 European countires till the end of 2011.

2010

UDCA Designation

In 2010 EMA designated UDCA an "orphan medicine" status — a medicine used for the treatment of primary biliary cholangitis.

2008

Renaissance of Interferon (IFNα)

IFNα has been used to treat malignant and viral disorders for more than 25 years.

A few clinical trials starting from 2008 showed that interferon is effective in normalizing blood counts, reducing the mutant JAK2 allele burden and, in some cases, reversing disease progression.

2005

JAK2 Discovery

The Janus Kinase 2 gene (JAK2) was discovered in 2005. It provides instructions to cells for making the JAK2 protein. The test looks for mutations in JAK2 that are associated with bone marrow disorders caused by the production of too many blood cells.

2005

Prostacyclin Analogues Approval

Subcutaneous prostacyclin analogue approved for the treatment of pulmonary arterial hypertension (PAH) in Europe.

2004

European Union Expansion

The European Union (EU) has expanded several times throughout its history via the accession of new member states. The EU expansion towards Eastern and Central Europe and the Western Balkans had a positive influence on the territorial expansion of AOP Orphan as well, creating a basis for providing treatments for rare diseases in all AOP Orphan core markets.

2001

1st Approval of Anagrelide in Europe

First marketing authorization for Anagrelide in Austria for treatment of patients with essential thrombocythemia.

1999

The Orphan Regulation EC no 141/2000

European Parliament adopted Regulation EC No 141/2000 The Orphan Regulation of Dec 16th, 1999. The Regulation lays down the EU procedure for the designation of orphan medicines, defines incentives for the development and placing of designated orphan medicines in the market, and establishes the Committee for Orphan Medicinal Products (COMP).

1996

Foundation of AOP Orphan in Vienna

Dr. Rudolf Widmann established a successful innovative pharmaceutical company focussed on the treatment of rare diseases in 1996 in Vienna, Austria.

Corporate culture

Thanks to many years of experience in the provision of complex and individualized treatments, AOP Health gained special expertise and market presence in the field of rare diseases.

Since its very start AOP Health has borne the corporate responsibility of further life quality improvement for patients with severe, rare and life-threatening diseases.  We at AOP Health conduct intensive research for this purpose, believing that developing and providing solutions for patients is the most important part of the AOP Health corporate responsibility. When it comes to wanting the best for the patients, we stand side-by-side with each other as a team, with researchers, physicians, therapists, caregivers and, patient organizations.

AOP Health is keen to keep one of its greatest assets – it is closely networked with the key specialists in all markets and is therefore able to help patients with rare diseases from Austria throughout the world.

1
Mag. Andreas Steiner Group CEO AOP Health Group

From its inception AOP Health's culture is shaped by the entrepreneurial spirit of its founder. We are proud to be a company that encourages employees to come up with new ideas and to show ownership and initiative every day. To help neglected patients with rare diseases is our key motivator. Through close interaction with the scientific community, care givers and partners we aim to provide therapies and help patients beyond just providing drugs.

The future

Thanks to our advancements in the field of therapies, an increasing number of patients survive their disease or are able to live with it for a longer period of time. In the next few decades, personalized medicine, individual treatment opportunities will emerge more and more as the standard in AOP Health’s therapy concepts as well.

Novel technologies such as next-generation sequencing (NGS) will play an equally crucial role as the increasing quantities of big data and conclusions derived from the daily lives of patients also beyond the strictly regulated conditions of clinical trials, e.g. real-world evidence.

Furthermore, the increasing health competence, health literacy of patients and their family members will also determine the future of pharma and health care sector.

WISSENSCHAFT & INNOVATION
Vom Konzept bis zum Medikament

Das AOP Health Headquarters Team in Wien deckt alle wesentlichen Aspekte der Produktentwicklung ab, angefangen bei der präklinischen Forschung und Toxikologie über die pharmazeutische und klinische Entwicklung bis hin zu regulatorischen Angelegenheiten, Qualitätsmanagement und Pharmakovigilanz. Erfahren Sie mehr auf der globalen Website auf Englisch

MEHR auf der globalen seite
NETZWERK WELTWEIT
Kooperationen

Die Kooperationen sind für AOP Health von zentraler Bedeutung. Diese ermöglichen die Weiterentwicklung des Portfolios für seltene Krankheiten von AOP Health und den Zugang von PatientInnen außerhalb der Kernmärkte des Unternehmens in Europa. Erfahren Sie mehr über die Möglichkeiten der Zusammenarbeit mit AOP Health auf der globalen Website auf Englisch

MEHR auf der globalen seite